The table provides details of approved research proposals that have published or presented their results.
|Data Request ID||Lead Investigator||Institution||Research Proposal Title||Publication|
|4036||Akira Kimata||University of Tsukuba||Optimal interruption time of dabigatran per OS to Ablation (O-A time) in patients with atrial fibrillation Integrated analysis of 2 randomized controlled clinical trials||Circulation. Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association’s Scientific Sessions 2019 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2019, Volume: 140, Issue: 25, Pages: e965-e1011, DOI: (10.1161/CIR.0000000000000742)
|3320||John Frew||Rockefeller University||Analysis of Outcome Measures in Hidradenitis Suppurativa/||Clinical Response Rates, Placebo Response Rates and Significantly Associated Covariates Are Dependent Upon Choice of Outcome Measure in Hidradenitis Suppurativa: A Post-Hoc Analysis of PIONEER 1 and 2 Individual Patient Data
Frew, John W. et al.
Journal of the American Academy of Dermatology, Volume 0, Issue 0
|4117||John Frew||Rockefeller University||Predictors of Treatment Response, Adverse Events, Changes in Anaemia status and Assessment of Lesion Count Variability in Hidradenitis Suppurativa||Malignancy and Infection Risk During Adalimumab Therapy in Hidradenitis Suppurativa. Frew, J., Jiang, C., Singh, N., Grand, D., Navrazhina, K., Vaughan, R. and Krueger, J. (2020), Clin Exp Dermatol. Accepted Author Manuscript.
Publications about Vivli and Data Sharing
Li, R. (2019). Move Clinical Trial Data Sharing from an Option to an Imperative – STAT First Opinion. [online] STAT.
Li, R., J. Scott, F. Rockhold, N. Hill, J. Wood, and I. Sim. (2018). Moving Data Sharing Forward: The Launch of the Vivli Platform . NAM Perspectives. Commentary, National Academy of Medicine, Washington, DC.